CT-guided 125I radioactive seed interstitial implantation combined with chemotherapy for advanced pancreatic carcinoma:analysis of therapeutic efficacy
10.3969/j.issn.1008-794X.2015.06.007
- VernacularTitle:CT引导下125I放射性粒子植入联合化疗对中晚期胰腺癌的疗效
- Author:
Junjie LUN
;
Junling ZHAO
;
Jianye SUN
;
Xiaokun HU
;
Haozhi YIN
- Publication Type:Journal Article
- Keywords:
pancreatic carcinoma;
125I seed;
gemcitabine;
Gio
- From:
Journal of Interventional Radiology
2015;(6):494-497
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of CT-guided 125I radioactive seed implantation combined with gemcitabine and Gio (gemcitabine and S-1, GS scheme) chemotherapy in treating advanced pancreatic carcinoma. Methods Sixty-eight patients with inoperable advanced pancreatic carcinoma were randomly divided into two groups. Patients in group A(n=38) were treated with CT-guided 125I radioactive seed implantation combined with GS chemotherapy scheme, while patients in group B (n=30) received GS chemotherapy scheme only. The short-term effect, the median progression-free survival time, the median survival time and adverse reactions of the two groups were determined , and the results were compared between the two groups. Results The objective response rate (ORR), disease control rate (DCR) and clinical benefit rate (CBR) of the group A were 57.9%, 73.7%and 84.2%respectively, while those of group B were 26.7%, 46.7% and 60.0% respectively. The differences between the two groups were statistically significant (P<0.05). In group A the median progression-free survival time and the median survival time were 8.00 months and 11.84 months respectively, which were strikingly higher than those in group B (5.63 months and 10.40 months respectively), the differences between the two groups were statistically significantly (P<0.05). No significant differences in gastrointestinal reactions, blood toxicity, liver toxicity and other adverse reactions existed between the two groups (P>0.05). Conclusion For advanced pancreatic carcinoma, CT-guided 125I radioactive seed implantation combined with GS program is a safe and effective treatment.
